China Approves Eli Lilly's Weight-Loss Pill orforglipron

what happened

China's medicine regulator has approved Eli Lilly's oral weight-loss drug orforglipron, Reuters reports. The decision, announced on Thursday, gives the American drugmaker an early advantage over Denmark's Novo Nordisk in the world's second-largest pharmaceutical market. The pill will compete for patients with once-weekly GLP-1 injections sold by Novo, Pfizer and the local company Innovent Biologics.

China's National Health Commission has said the share of overweight or obese people could exceed 65% by 2030. Both Novo and Lilly believe pills could draw patients who avoid injections. Novo's own oral Wegovy has not yet been approved in China, and Lilly was the first company to file for orforglipron.

why it matters

For markets, the approval strengthens Lilly's position in a fast-growing obesity drug market and adds pressure on Novo Nordisk's share in China. Oral options could widen the patient pool, which matters for both companies' revenue outlooks.

market impact

Novo Nordisk: stronger competition in China puts pressure on the shares; Lilly gains from the approval

• ▼Novo Nordisk shares pressure down — lilly's early lead in China intensifies competition in the obesity drug market
• ▲Eli Lilly shares pressure up — the Chinese approval opens a large market to the company ahead of rivals

tags

instruments